Although PI3K-inhibitors are vital anticancer drugs 4,5,7,12,13,15-17, only the PI3Kα isoform-inhibitor Piqray (Alpelisib, Novartis) is FDA-approved for breast cancer so far 18. Here, PIK3CA is linked to breast cancer.